Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2017-07-14 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
独立董事工作制度
Governance Information Classification · 95% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System'. It details the governance structure, qualifications, duties, powers, and working procedures of independent directors in the company. The content focuses on internal governance rules, director responsibilities, and compliance with regulatory requirements related to board members. There is no financial data, no mention of financial results, no voting results, no announcements of meetings, or any other report type. The document is a governance-related policy document outlining internal rules and practices for independent directors. Therefore, it fits best under the category of Governance Information (CGR). The document length (6714 characters) supports it being a full policy document rather than a brief announcement or certification.
2017-07-14 Chinese
董事会战略委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the "细胞基因工程股份有限公司 董事会战略委员会工作细则" which translates to "Rules of Procedure for the Board Strategic Committee". It details the composition, responsibilities, meeting procedures, voting rules, and other governance-related matters of the company's Board Strategic Committee. There is no financial data, no mention of financial results, no regulatory filings, no voting results, no announcements of dividends, no audit information, no earnings data, no capital changes, no legal proceedings, no merger or acquisition activity, and no investor presentation content. The document is a governance-related internal rules document about the board committee structure and procedures. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 3911 characters, which is sufficient for a detailed governance document. Therefore, the classification is CGR with high confidence.
2017-07-14 Chinese
董事会秘书工作制度
Governance Information Classification · 95% confidence The document is titled '董事会秘书工作制度' which translates to 'Board Secretary Work System'. It details the duties, qualifications, appointment, and responsibilities of the company's board secretary. The content is about governance practices and internal rules related to the board secretary role, referencing company law, stock exchange listing rules, and company bylaws. There is no financial data, earnings information, or report publication mentioned. The document is a governance-related policy document rather than a report or announcement. Therefore, it fits best under Governance Information (CGR). The document length is 4091 characters, which is not extremely short, and it is not an announcement or certification. Hence, the classification is CGR with high confidence.
2017-07-14 Chinese
独立董事提名人声明（张平）
Board/Management Information Classification · 95% confidence The document is a formal statement nominating an independent director candidate for the company's board. It details the nominee's qualifications, compliance with legal and regulatory requirements, and independence criteria. There is no financial data, no report or presentation content, and no announcement of voting results or management changes. The document is a declaration related to board nominations, which fits best under Board/Management Information (MANG). The document length is short and focused solely on nomination, not a full report or announcement of a meeting result.
2017-07-14 Chinese
独立董事候选人声明（陈敏）
Board/Management Information Classification · 95% confidence The document is a declaration statement by an independent director candidate, Chen Min, confirming qualifications, independence, and compliance with regulatory requirements for serving as an independent director of a listed company. It includes detailed personal qualifications, legal compliance, and commitments related to the role. There are no financial statements, no report attachments, no voting results, no management changes, and no financial or regulatory filings per se. This is a formal declaration related to board/management information, specifically about a director candidate's qualifications and independence. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and focused on a single candidate's declaration, consistent with such announcements.
2017-07-14 Chinese
董事会薪酬与考核委员会工作细则
Remuneration Information Classification · 95% confidence The document is a detailed set of rules and procedures for the Board's Remuneration and Assessment Committee, including its composition, responsibilities, meeting procedures, and remuneration assessment processes. It focuses on governance and internal management of executive compensation and performance evaluation. There is no financial data, no report of financial results, no announcement of voting results, no legal proceedings, no capital changes, and no investor presentation. The content aligns with governance and remuneration practices. Therefore, the document fits best under the category of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors.
2017-07-14 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.